Creo Medical Group plc provided revenue guidance for the year ending December 31, 2021. The group expects to report overall revenue for the year ended 31 December 2021, ahead of expectations, at just over £25 million, despite the well documented challenges related to COVID-19. Revenue from the company's core Creo product portfolio is growing and is in-line with management's cumulative revenue forecasts at the time of IPO in December 2016.